Biotech stocks succumbed to the broader market weakness, as trade tensions and recession fears shook the broader markets. Earnings and stray clinical readouts triggered some activity in the space.
Here are the key biotech catalysts for the unfolding week.
Conferences
- The World Heart Congress – Aug. 19-20, in Vienna, Austria
- 11th international Conference on Clinical and Cellular Immunology – Aug. 22-23, in Vienna
- 2019 Asia-Pacific Prostate Cancer Conference – Aug. 24-26, in Melbourne, Australia
PDUFA Dates
Nabriva Therapeutics PLC – ADR NBRV 5.56% awaits FDA decision on its NDA for intravenous and oral formulations of Lefamulin for treating community-acquired bacterial pneumonia. The PDUFA date is set for Monday, Aug. 19.
Sarepta Therapeutics Inc SRPT 2.44%‘s NDA for Duchenne muscular dystrophy drug Golodirsen has a FDA action date of Monday. Golodirsen is being studied by Sarepta for the treatment of exon 53 amenable patients, who account for about eight percent of DMD patients.
Clinical Trial Readout
TrovaGene Inc TROV 28.22% is due to present new Phase 2 data for Onvansertib and Zytiga at the Asia-Pacific Prostate Cancer Conference Saturday, Aug. 24.
Earnings
Tuesday, Aug. 20
Medtronic PLC MDT 1.05%
IPO Quiet Period Expiry
Castle Biosciences Inc CSTL 1.22%
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.